Novel Allogenic CD19-targeting Chimeric Antigen Receptor γδT Cells Therapy (QH103E) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The QH103E therapy represents a novel approach in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) by utilizing allogeneic γδT cells engineered to express a CD19-targeting CAR. The market for CAR T-cell therapies is rapidly expanding, with significant demand for innovative treatments in hematological malignancies. Given the increasing prevalence of NHL and the limitations of existing therapies, QH103E could capture a substantial share of this market if proven effective and safe. Competitive analysis indicates that while there are established players in the CAR T-cell space, the unique mechanism of action and potential for enhanced memory efficacy may provide a differentiated position. Diligence should focus on the regulatory pathway, potential partnerships, and reimbursement strategies, particularly in the context of the Chinese healthcare system.
Indication: Non-hodgkin Lymphoma,B Cell
Modality: protein therapy
Target: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells
Sponsor: Chinese PLA General Hospital
Source URL: ClinicalTrials.gov
Source updated: Jul 30, 2025
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells
View original source fields
Condition raw: Non-hodgkin Lymphoma,B Cell
Condition normalized: Non-hodgkin Lymphoma,B Cell
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells
Target normalized: CD19-targeting Chimeric Antigen Receptor (CAR) on allogeneic γδT cells